(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...
The fund’s thesis comes during a time when diversity initiatives, programs, and focuses are under political and legal fire.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback